Moffitt Cancer Center Partners with TuHURA Biopharma Inc. to Develop a New Generation of Targeted Immunotherapies

Moffitt Cancer Center Partners with TuHURA Biopharma Inc. to Develop a New Generation of Targeted Immunotherapies

TAMPA, Fla. and SEATTLE – Moffitt Cancer Center announced today a licensing agreement with TuHURA Biopharma, Inc., a start-up biotechnology company in Seattle, to develop new immunotherapy treatments for cancer that will apply to a greater number of cancers and a larger patient population.

Full Story

Related posts

University of Miami aims test program at Miami Beach shoreline

A University of Miami interdisciplinary team is seeking permits from the State of Florida and…

Florida Universities Get Grants To Boost Telehealth Training

The federal Health Resources and Services Administration has awarded $15 million in grants nationwide, including…

Innovation and research at USF take center stage during pandemic, with increased patent production and funding

The University of South Florida may have steered its students away during the coronavirus pandemic,…